Sunnybrook Hospital

Running trials

• Recruiting

  A Post Authorization Registry Study of Participants Treated With LEQEMBI

  NCT07762092· Eisai Limited· Source

• Recruiting

  Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing

  NCT07387263· Unity Health Toronto· Source

• Recruiting

  The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

  NCT06455384· Unity Health Toronto· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Recruiting

  Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study

  NCT06249269· Ratika Parkash· Source

• Recruiting

  Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

  NCT05298124· Ottawa Heart Institute Research Corporation· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Recruiting

  The DRAGON 2 Trial

  NCT05428735· Maastricht University· Source

• Active, not recruiting

  A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

  NCT04974398· Phase 3· Akeso· Source

• Recruiting

  Statins for Venous Event Reduction in Patients With Venous Thromboembolism

  NCT04319627· Phase 3· Ottawa Hospital Research Institute· Source

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· University of British Columbia· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

• Active, not recruiting

  Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

  NCT02503423· Phase 1/2· Taiho Oncology, Inc.· Source

• Recruiting

  Nephrotic Syndrome Study Network

  NCT01209000· University of Michigan· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• Colorectal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Alzheimer disease1 recruiting
• Aortic stenosis1 recruiting
• Coronary artery disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Epilepsy1 recruiting
• Nephrotic syndrome1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

  NCT04485195· Phase 4· Ottawa Hospital Research Institute· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Population Health Research Institute· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Mild cognitive impairment23 works · 0 trials